Question 1

Why is plain turmeric powder considered ineffective?

Accepted Answer

Curcumin — the principal bioactive in turmeric — has very low oral bioavailability. It is poorly absorbed across the intestinal wall, rapidly metabolised by glucuronidation and sulfation in the gut wall and liver, and excreted before it can exert systemic effects. Pharmacokinetic studies show plasma concentrations after standard turmeric powder are negligible. Bioavailability-enhanced formulations address this: Meriva (phytosome with phosphatidylcholine) achieves ~29-fold greater absorption than standard curcumin; Theracurmin (submicron colloidal dispersion) ~27-fold; BCM-95 (with turmeric essential oil) ~7-fold; and curcumin combined with piperine (black pepper extract) ~20-fold. Most clinical evidence comes from these enhanced forms — not plain turmeric.

Question 2

What does the MHRA say about turmeric supplements?

Accepted Answer

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued precautionary guidance after case reports of acute liver injury, some severe, linked to high-strength turmeric/curcumin food supplements — particularly those formulated with piperine or marketed as enhanced bioavailability. Users are advised to stop the supplement and seek medical advice if they develop jaundice (yellow skin or eyes), dark urine, persistent nausea, abdominal pain, or unexplained fatigue. The risk is small in absolute terms but real, and is the strongest reason to use turmeric supplements only short-term and at sensible doses.

Question 3

Does curcumin actually work for joint pain?

Accepted Answer

The Daily 2016 meta-analysis of 8 RCTs (n=606) concluded that turmeric extracts at approximately 1,000 mg/day curcuminoids reduced knee osteoarthritis pain (WOMAC, VAS) comparably to ibuprofen, with fewer GI side effects. The Belcaro 2010 trial of Meriva (curcumin phytosome) reported significant WOMAC improvement at just 200 mg curcuminoids/day in phytosome form. NHS arthritis guidance emphasises exercise, weight management, and topical or oral NSAIDs first-line, but acknowledges that supplements such as curcumin and glucosamine/chondroitin are commonly used and may help some patients. The evidence is strongest for knee OA and weakest for general 'inflammation' marketing claims.

Question 4

What dose of curcumin is studied for joint pain?

Accepted Answer

Trials of standard turmeric extract have used 1,000–2,000 mg curcuminoids/day, typically split into 2 doses with food, for 8–12 weeks. Bioavailability-enhanced forms achieve clinical effect at lower doses: Meriva at 200 mg curcuminoids/day (in phytosome form), Theracurmin at 180 mg/day, BCM-95 at 1,000 mg/day. Time to noticeable benefit is generally 2–6 weeks. Curcumin is fat-soluble — taking with a fat-containing meal modestly improves absorption.

Question 5

Can I take turmeric with my medications?

Accepted Answer

Curcumin inhibits the cytochrome P450 3A4 enzyme system, which metabolises many prescription medicines. This can theoretically increase plasma levels of statins, calcium-channel blockers, ciclosporin, and many others. Curcumin also has antiplatelet effects and may potentiate warfarin, DOACs, aspirin and NSAIDs — increasing bleeding risk. In one published case series, turmeric supplements interfered with chemotherapy. Always check with a GP or pharmacist before combining turmeric supplements with prescription medication, particularly anticoagulants, antihypertensives, statins, or oncology drugs.

Question 6

Has EFSA authorised any health claim for turmeric or curcumin?

Accepted Answer

No. EFSA has not authorised any specific health claim for turmeric or curcumin under EU/UK retained nutrition and health claims regulation. Manufacturers cannot legally claim turmeric/curcumin treats inflammation, arthritis, or any disease in the UK. General marketing language tends to use phrases such as 'traditionally used' rather than authorised health claims. This is not a comment on the science — many promising bioactives have not made it through the EFSA dossier process — but UK consumers should not infer that the absence of regulatory claim equals the absence of evidence, nor that the presence of a 'traditional use' phrase equals proof.

Grade	Health Outcome	Studies	Participants	Effect
B	Knee Osteoarthritis Pain8 studies	8	606	Curcumin (typically as bioavailability-enhanced extract such as Meriva, BCM-95, or with piperine) reduces knee osteoarthritis pain comparably to ibuprofen, with fewer GI adverse events.
C	Systemic Inflammation Markers9 studies	9	600	Curcumin can lower CRP and other inflammatory markers in some populations (metabolic syndrome, diabetes), but effect is heterogeneous and dependent on formulation and bioavailability.
C	Hepatotoxicity (Safety Signal)0 studies	0	0	Increasing case reports of acute liver injury linked to high-strength turmeric supplements, particularly products with piperine or enhanced bioavailability. MHRA has issued precautionary guidance.

Turmeric & Curcumin

Evidence Database

Reviewed retailer prices

No reviewed retailer prices yet

General Information

Dosage (Evidence-Reported)

Safety Notes

Key Benefits

Quick Facts

Frequently Asked Questions